University of Missouri-Kansas City, Kansas City, Missouri; Saint Luke's Mid America Heart Institute, Kansas City, Missouri.
University of Missouri-Kansas City, Kansas City, Missouri.
Am J Cardiol. 2020 Apr 1;125(7):1046-1053. doi: 10.1016/j.amjcard.2019.12.045. Epub 2020 Jan 8.
Although contemporary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is performed with high success rates, 10% to 13% of patients presenting with CTOs have chronic kidney disease (CKD), and the comparative safety, efficacy, and health status benefit of CTO PCI in these patients, has not been well defined. We examined the association of baseline renal function with periprocedural major adverse cardiovascular and cerebral events and health status outcomes in 957 consecutive patients (mean age 65.3 ± 10.3 years, 19.4% women, 90.3% white, 23.6 CKD [estimated glomerular filtration rate {eGFR} < 60]) in the OPEN-CTO (Outcomes, Patients Health Status, and Efficiency in Chronic Total Occlusions Registry) study. Hierarchical multivariable regression models were used to examine the independent association of baseline eGFR with technical success, periprocedural complications and change in health status, using Seattle Angina Questionnaire (SAQ) over 1 year. Crude rates of acute kidney injury were higher (13.5% vs 4.4%, p <0.001) and technical success lower (81.8% vs 88.4%, p = 0.01) in patients with CKD. There were no significant differences in other periprocedural complications. After adjustment for confounding factors, there was no significant association of baseline eGFR with technical success or periprocedural major adverse cardiovascular and cerebral events (death, myocardial infarction, emergent bypass surgery, stroke, perforation), whereas patients with lower eGFR had higher rates of acute kidney injury. The difference in SAQ summary score, between patients on the 10th and 90th percentile for baseline eGFR distribution was not clinically significant (1 month: -0.91; 1 year: -3.06 points). In conclusion, CTO PCI success, complication rates, and the health status improvement after CTO PCI are similar in patients across a range of baseline eGFRs.
虽然当代慢性完全闭塞(CTO)经皮冠状动脉介入治疗(PCI)的成功率很高,但 10%-13%的 CTO 患者患有慢性肾脏病(CKD),而这些患者 CTO PCI 的安全性、疗效和健康状况获益尚未得到很好的定义。我们在 OPEN-CTO(慢性完全闭塞患者的结局、患者健康状况和效率注册研究)研究中,检查了 957 例连续患者(平均年龄 65.3±10.3 岁,19.4%为女性,90.3%为白人,23.6%为 CKD[估算肾小球滤过率{eGFR}<60])的基线肾功能与围手术期主要不良心血管和脑事件及健康状况结局的相关性。使用西雅图心绞痛问卷(SAQ)在 1 年内评估,使用分层多变量回归模型来检查基线 eGFR 与技术成功率、围手术期并发症和健康状况变化的独立相关性。在 CKD 患者中,急性肾损伤的发生率更高(13.5%比 4.4%,p<0.001),技术成功率更低(81.8%比 88.4%,p=0.01)。其他围手术期并发症无显著差异。在调整混杂因素后,基线 eGFR 与技术成功率或围手术期主要不良心血管和脑事件(死亡、心肌梗死、紧急旁路手术、中风、穿孔)无显著相关性,而 eGFR 较低的患者发生急性肾损伤的比例较高。SAQ 综合评分在基线 eGFR 分布的第 10 百分位和第 90 百分位之间的患者之间的差异无临床意义(1 个月:-0.91;1 年:-3.06 分)。总之,在一系列基线 eGFR 范围内,CTO PCI 的成功率、并发症发生率和 CTO PCI 后的健康状况改善在患者中相似。